Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 12.93% is 116% above its 5-year average of -81.94%, near the high end of its 5-year range (-572.62%–12.93%).
As of the fiscal period ended Tuesday, June 30, 2026. 170.27% above its 12-month average of -18.40%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 12.93%.
RETURN ON EQUITY (ROE)
12.93%
RETURN ON EQUITY (ROE) AVG TTM
-18.40%
RETURN ON EQUITY (ROE) AVG 3Y
-59.99%
RETURN ON EQUITY (ROE) AVG 5Y
-81.94%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+170.27%
CURRENT VS 3Y AVG
+121.55%
CURRENT VS 5Y AVG
+115.78%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
+130.78%
vs the sector median at left
Arcutis Biotherapeutics, Inc.
Market Cap
$2.99B
Return on Equity (ROE)
12.93%
TTM Avg
-18.40%
3Y Avg
-59.99%
5Y Avg
-81.94%
Market Cap
$3.03B
Return on Equity (ROE)
-11.83%
TTM Avg
-25.64%
3Y Avg
-7.84%
5Y Avg
-12.83%
Market Cap
$3.06B
Return on Equity (ROE)
-61.24%
TTM Avg
-42.47%
3Y Avg
-32.58%
5Y Avg
-25.72%
Market Cap
$2.88B
Return on Equity (ROE)
-73.97%
TTM Avg
-48.15%
3Y Avg
-105.34%
5Y Avg
-79.84%
Market Cap
$3.12B
Return on Equity (ROE)
-63.59%
TTM Avg
-115.27%
3Y Avg
-69.35%
5Y Avg
-25.98%
Market Cap
$3.19B
Return on Equity (ROE)
-13.40%
TTM Avg
-35.40%
3Y Avg
-42.99%
5Y Avg
-32.74%
Market Cap
$2.77B
Return on Equity (ROE)
29.28%
TTM Avg
27.86%
3Y Avg
4.54%
5Y Avg
-12.45%
Market Cap
$2.73B
Return on Equity (ROE)
2.04%
TTM Avg
-6.01%
3Y Avg
-7.18%
5Y Avg
-5.00%
Market Cap
$2.71B
Return on Equity (ROE)
-25.47%
TTM Avg
-23.80%
3Y Avg
14.67%
5Y Avg
14.67%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | $2.99B | 12.93% | -18.40% | -59.99% | -81.94% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.03B | -11.83% | -25.64% | -7.84% | -12.83% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.06B | -61.24% | -42.47% | -32.58% | -25.72% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | -73.97% | -48.15% | -105.34% | -79.84% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.12B | -63.59% | -115.27% | -69.35% | -25.98% |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | -13.40% | -35.40% | -42.99% | -32.74% |
| TransMedics Group, Inc. (TMDX)vs › | $2.77B | 29.28% | 27.86% | 4.54% | -12.45% |
| AtriCure, Inc. (ATRC)vs › | $2.73B | 2.04% | -6.01% | -7.18% | -5.00% |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.71B | -25.47% | -23.80% | 14.67% | 14.67% |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.70B | -56.91% | -24.13% | -9.83% | -11.19% |
ROE
12.9%
ROA
5.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 12.93% |
| 2026-03-31 | -1.25% |
| 2025-12-31 | -8.52% |
| 2025-09-30 | -28.04% |
| 2025-06-30 | -67.11% |
| 2025-03-31 | -90.93% |
| 2024-12-31 | -88.89% |
| 2024-09-30 | -124.83% |
| 2024-06-30 | -106.62% |
| 2024-03-31 | -96.66% |
| 2023-12-31 | -295.24% |
| 2023-09-30 | -572.62% |
| 2023-06-30 | -410.46% |
| 2023-03-31 | -233.93% |
| 2022-12-31 | -148.61% |
| 2022-09-30 | -114.77% |
| 2022-06-30 | -133.09% |
| 2022-03-31 | -92.46% |
| 2021-12-31 | -69.32% |
| 2021-09-30 | -46.58% |
| 2021-06-30 | -36.26% |
| 2021-03-31 | -31.86% |
| 2020-12-31 | -50.14% |
| 2020-09-30 | -65.98% |
| 2020-06-30 | -43.30% |
| 2020-03-31 | -26.19% |
| 2019-12-31 | -41.39% |
| 2019-06-30 | -84.02% |
| 2019-03-31 | -47.49% |
